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Abstract
Background & Aims: Patients with drug-induced liver injury (DILI) frequently have comorbid 
conditions, but the effects of non-liver comorbidities on outcome is not well understood. We 
investigated the association between co-morbidity burden and outcomes of patients with DILI, and 
developed and validated a model to calculate risk of death within 6 months.
Methods: A multiple logistic regression model identified variables independently associated with 
death within 6 months of presenting with suspected DILI (6-month mortality) for 306 patients 
enrolled in the DILIN prospective study at Indiana University (discovery cohort). The model was 
validated using data from 247 patients with suspected DILI enrolled in the same study at the 
University of North Carolina (validation cohort). Medical comorbidity burden was calculated 
using the Charlson comorbidity index—patients with scores higher than 2 were considered to have 
significant comorbidities.
Results: Six-month mortality was 8.5% in the discovery cohort and 4.5% in the validation 
cohort. In the discovery cohort, significant comorbidities (odds ratio [OR], 5.4; 95% CI 2.1 – 
13.8), model for end-stage liver disease score (OR, 1.11; 95% CI, 1.04–1.17), and serum level of 
albumin at presentation (OR, 0.39; 95% CI, 0.2–0.76) were independently associated with 6-
month mortality. A model based on these 3 variables identified patients who died within 6 months 
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with c-statistic values of 0.89 (95% CI, 0.86–0.94) in the discovery cohort and 0.91 (95% CI, 
0.83–0.99) in the validation cohort. We developed a web-based calculator to determine risk of 
death within 6 months for patients with suspected DILI for use in the clinic.
Conclusions: We developed and validated a model based on comorbidity burden, model for 
end-stage liver disease score, and serum level of albumin that predicts 6-month mortality in 
patients with suspected DILI.
Keywords
MELD; CCI; DILIN Prospective Study
Introduction
Drug-induced liver injury (DILI) is an important cause of liver-related morbidity and 
mortality that is likely under-recognized. Its diagnosis depends on high index of suspicion, 
compatible temporal relationship, and thorough exclusion of competing etiologies1. DILI by 
an implicated drug, commonly occurs in patients with one or several comorbid conditions 
such as hypertension, diabetes mellitus, cardiovascular disease, renal disease and 
malignancy. The Drug-Induced Liver Injury Network (DILIN) Prospective Study enrolls 
individuals with suspected DILI at several clinical centers across the United States (1). A 
recent paper from the DILIN Prospective Study reported suspected agents and selected 
clinical features and outcomes of patients with DILI (2). Approximately 82% of patients 
enrolled in DILIN with suspected DILI and completing the causality assessment were 
determined to have probable, very likely or definite DILI2. Importantly, 10% of over 1,000 
patients with DILI enrolled in DILIN suffered death or required liver transplantation within 
2 years of DILI onset, with DILI playing a primary or contributory role in 80% of those 
deaths or transplants3. In approximately three quarters of these cases, there was evidence of 
acute liver failure, although in other cases there was more prolonged injury and chronicity 
preceding death3. A new Hy’s law was proposed in patients with a hepatocellular injury 
pattern and serum total bilirubin greater than 2.5 mg/dL being predictive of DILI-related 
mortality or liver transplantation, although 40% of cases of death or liver transplantation 
presented with a mixed or cholestatic injury pattern3. The most common non-DILI causes of 
death were related to co-morbid conditions, including malignancy, cardiovascular or 
cerebrovascular diseases, acute or chronic respiratory diseases, neurologic diseases, diabetes 
mellitus, and renal disease3.
A recent study suggested that medical comorbidity contributes to mortality risk in patients 
with hepatitis C infection independent of cirrhosis4. Additionally, medical comorbidity also 
predicts short-term mortality in acutely ill patients receiving intensive care5. In one study, a 
model combining medical comorbidity scores with a liver specific model was more 
discriminating in predicting hospital mortality in cirrhosis6. Anecdotally, we observed that 
some individuals with significant comorbidities succumbed to relatively minor DILI events 
whereas others without significant comorbidities survived severe DILI events. However, the 
impact of comorbidity burden on mortality in patients with suspected DILI has not been 
investigated previously. In this study we show that comorbidity burden is independently 
associated with mortality in individuals presenting with suspected DILI. Further, we 
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developed and validated a robust model consisting of comorbidity burden, MELD and serum 
albumin to predict 6 month mortality among individuals presenting with suspected DILI.
Methods
Our discovery cohort consisted of consecutive patients with suspected DILI enrolled in the 
DILIN Prospective Study at Indiana University between 2003 and 2017. The DILIN 
Prospective study () is a multicenter observational study of patients aged 2 years or older 
with suspected liver injury meeting predefined biochemical criteria for liver test 
abnormalities7. Enrolled patients were clinically characterized in a standardized fashion and 
the likelihood of DILI was adjudicated by consensus7. We analyzed demographic and 
clinical data, including implicated agents, and outcomes of DILI. The pattern of liver injury 
at presentation was defined using R value (the ratio of alanine aminotransferase (divided by 
its upper limit of normal) to alkaline phosphatase (divided by the upper limit of normal)), as 
cholestatic (R<2), mixed (R=2 to 5) or hepatocellular (R>5). We recorded the comorbidities 
and long term mortality data from medical records and from the DILIN case report forms. 
The primary outcome of interest was mortality within 6 months of onset of liver injury, and 
we also described overall mortality up to last follow-up. Participants in this report have been 
part of a number of papers published by the DILIN3, 8–12. This study has been approved the 
Institutional Review Boards at Indiana University and the University of North Carolina, and 
all participants signed an informed consent.
The medical comorbidity burden at presentation was quantified using the Charlson 
Comorbidity Index (CCI)13. For this study purposes, we grouped patients into those with no 
or mild medical comorbidity (CCI range from 0 to 75th percentile value) and significant 
comorbidity (CCI >75th percentile). Descriptive analyses included comparison of clinical 
characteristics according to CCI groups. The first available INR, serum total bilirubin and 
creatinine, at or after onset of liver injury, were used to calculate MELD. We analyzed the 
association of significant comorbidity, with 6-month mortality in all patients. Furthermore, 
we assessed the interaction of significant comorbidity and severe liver injury, defined as an 
initial MELD>19, on 6-month mortality risk, as a previously described threshold for 
increased mortality in the DILIN experience3.
Comparison of categorical variables between study groups, including 6-month mortality, 
was performed using the chi-square test. Comparison of continuous data between groups 
was performed using nonparametric tests, including Wilcoxon or Kruskal Wallis tests. 
Overall mortality was analyzed using the Kaplan Meier method with log-rank for differences 
between groups. The independent predictors of 6-month mortality were examined using 
simple and multiple logistic regression analyses. The resulting model was validated on a 
separate cohort of prospectively enrolled subjects in the DILIN Prospective Study during the 
same period at the University of North Carolina. A calculator based on the regression 
coefficients was developed to estimate 6-month mortality in patients with suspected acute 
DILI. A p-value <0.05 was considered statistically significant for all analyses.
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Patient and liver injury characteristics
The discovery cohort consisted of 306 patients, mean (SD) age 49 ± 19 years and 48% male. 
The most frequent conditions contributing to CCI were diabetes and pulmonary disease 
(15% each), and malignancy, liver disease, peripheral vascular disease, renal disease, 
congestive heart failure and stroke (4.8 to 6% each). The median CCI was 0 (interquartile 
range 0, 2), and 253 patients (83%) with CCI ≤ 2 were classified to have “none to mild 
comorbidity,” whereas 53 patients (17%) with CCI > 2 were classified to have “significant 
comorbidity”. We compared select participant and liver injury characteristics of individuals 
with suspected DILI according to this categorization of comorbidity (Table 1). Compared 
with none to mild comorbidity group, patients with significant comorbidity were older, and 
more likely to be male and black. The mean MELD in the entire cohort was 15 ± 7, and it 
was higher in those with significant comorbidity, which was driven primarily by worse renal 
function in that subgroup. The pattern of liver injury in patients with significant comorbidity 
was more frequently cholestatic and less frequently hepatocellular, compared to none/mild 
comorbidity. The most common class of implicated agent was antimicrobials with no 
significant differences between groups. However, herbal and dietary supplements were 
predominantly implicated in patients with none to mild comorbidity, while cardiovascular 
agents were predominantly implicated in patients with significant comorbidity. Patients with 
significant comorbidity had a trend towards a higher number of implicated agents and 
significantly more concomitant medications compared to patients with none to mild 
comorbidity (Table 1).
Comorbidity and clinical outcomes
The mean follow-up in the study cohort was 49 ± 44 months (median 38 months, 
interquartile range 8, 84). Of the 306 patients included, 4 (1.3%) underwent subsequent liver 
transplantation, and all 4 had no comorbidity. The implicated agents in these 4 cases 
included: mercaptopurine, diphenoxylate with atropine sulfate and 2 herbal and dietary 
supplements labelled as ephedrine and vitamins with minerals not otherwise specified. 
Overall, 49 patients (16%) died at any time after the onset of liver injury. Higher mortality 
was observed in patients with significant comorbidity, compared to those with none to mild 
comorbidity (Figure 1). However, death was assessed as liver-related in only 36% of patients 
with significant comorbidity who died, compared with 64% with no/mild comorbidity 
(p=0.1) using previously reported methodology to adjudicate the role of DILI in death or 
liver transplantation3. Mortality within 6 months of suspected DILI presentation was 
observed in 26/253 (10.3 %) of patients with none to mild, but in 15/53 (28.3%) in patients 
with significant comorbidity (p<0.001). The drugs implicated in these 26 cases included 
antimicrobial (13), antineoplastic (6), cardiovascular (6) and a unknown (1) agent 
(Supplemental Table 1). The causes of death in patients with and without significant 
comorbidity are described in Supplemental Table 2, with 4 cases of death due to acute on 
chronic liver failure.
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Multiple logistic regression analysis identified significant comorbidity (OR 5.2, 95% CI 2.1 
– 13.3), MELD (OR 1.09, 95% CI 1.03–1.15), and serum albumin (OR 3.7, 95% CI 0.2 
−0.7) as the independent predictors of 6-month mortality in individuals with suspected DILI 
(Table 2). The multiple logistic regression model performed well in predicting 6-month 
mortality, with a c-statistic of 0.89 (95% confidence interval: 0.86 – 0.94) with good fit 
(Hosmer and Lemeshow Goodness-of-Fit Test, Chi-square = 9.2, p = 0.3).
Significant comorbidity was significantly associated with six-month mortality when the 
analysis was restricted to those who were adjudicated to have definite, highly likely, or 
probable DILI (OR: 7.4, 95% CI: 1.9 – 28.6, p=0.004). A previous study [3] has shown 
that MELD is a strong predictor of mortality in patients with suspected DILI3 For 
descriptive purposes, we examined the relationship between CCI and 6 month mortality after 
stratifying our cohort into MELD ≤ 19 and MELD > 19 subgroups, since that MELD 
threshold was sensitive and specific for predicting mortality in DILI3. Compared to none to 
mild comorbidity, significant comorbidity was associated with higher 6-month mortality 
among individuals with MELD ≤ 19 (20% vs 2.4%, p=0.001) as well as MELD > 19 (39.1% 
vs 13.3%, p=0.01) (Table 3). There was no interaction between CCI and MELD >19 (p 
value=0.31). This highlights the increased risk of short-term mortality associated with 
significant comorbidity in patients with suspected DILI, regardless of MELD related risk. In 
a sensitivity analysis, when we limited our analysis to 231 patients with high confidence 
DILI cases (causality scores: definite, highly likely, and probable), CCI>2 was a significant 
predictor of 6 month mortality, even after controlling for albumin and MELD, with the 
model achieving a c-statistic of 0.92 (95% confidence interval: 0.87 – 0.98) with good fit 
(Hosmer and Lemeshow Goodness-of-Fit Test, Chi-square = 4.3, p = 0.8).
The validation cohort comprised 247 patients enrolled in DILIN at the University of North 
Carolina. Significant comorbidity was noted in 40 subjects (16%) and they were older with 
more males but similar racial distribution, more frequent cholestatic liver injury and less 
frequent hepatocellular injury compared with those with mild comorbidity, (Supplemental 
Table 3). Their 6-month mortality was 4.5%. Our multiple logistic regression model based 
on CCI, MELD, and serum albumin achieved a c-statistic of 0.91 (95% confidence interval: 
0.83 – 0.99) in the validation cohort, with good fit (Hosmer and Lemeshow Goodness-of-Fit 
Test, Chi-square = 5.4, p = 0.7) for predicting 6-month mortality in this validation cohort. 
We calculated the Brier score, which measures the accuracy of probabilistic predictions, in 
both derivation and validation cohorts. The lower the Brier score for a set of predictions, the 
better the prediction are calibrated. The Brier score for our model in the Indiana University 
derivation cohort was 0.038, and in the University of North Carolina validation cohort was 
0.0386.
A DILI mortality calculator representing the model incorporating CCI category, albumin and 
MELD to estimate the risk of 6-month mortality in patients with suspected acute DILI was 
developed and calibrated using the model derived from the Indiana University cohort (Figure 
2). The regression equations for calculating the risk score and the six-month mortality are 
described in Supplemental Table 4.
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In this prospective study of well-characterized patients with suspected DILI, approximately 
half of the patients suffered from medical comorbidity, as quantified using the Charlson 
Comorbidity Index. The main finding of this study was that medical comorbidity, and 
significant comorbidity in particular (CCI>2), were associated with increased risk of 6-
month and overall mortality. Patients with significant comorbidity did not undergo liver 
transplantation, but mortality was more frequently non liver-related, and likely related to the 
underlying comorbidity burden.
While not surprising, this finding is novel and highlights a previously unrecognized 
mortality risk for patients with DILI. Significant comorbidity independently predicted 6-
month mortality in addition to MELD and albumin, which have been described as important 
risk factors for mortality in patients with DILI3. A model comprising severity of 
comorbidity, MELD and albumin performed well (c-statistic 0.89) in the Indiana University 
derivation cohort. This model was validated in a prospectively studied cohort at the 
University of North Carolina and performed equally well in that cohort (c-statistic 0.91). A 
DILI mortality calculator was developed based on the model’s regression coefficients to 
estimate 6-month mortality based on model parameters. This dynamic web-based calculator 
was developed to facilitate application of the model in clinical practice, and can be accessed 
at http://gihep.com/calculators/hepatology/dili-cam/. Significant comorbidity burden 
remained an independent predictor of 6-month mortality when excluding patients with liver 
injury attributed to a non-DILI etiology. Since DILI is not a unique cause of liver injury, it is 
conceivable that models incorporating comorbidity burden and severity of liver injury could 
prove useful in improving the prediction of mortality in a variety of liver injuries and 
diseases, and as such warrants further studies.
A CCI score >2 would not be considered a high score in some studies exploring the impact 
of CCI that use a threshold of >3 based on highest quartile of CCI14. The CCI threshold of 
>2 in our study was derived mathematically using the 75th percentile for CCI in the 
derivation cohort for descriptive purposes. Subsequently, its significance with respect to risk 
of mortality was demonstrated in both the derivation and validation cohorts, lending 
credibility to the descriptor of “significant comorbidity” using this definition. This threshold 
(CCI > 2) has also been associated with mortality risk in general population studies and in 
patients present with acute heart failure15,16.
While MELD was higher in patients with significant comorbidity, the difference was 
predominantly related to chronic kidney disease and higher baseline serum creatinine in that 
subgroup. Significant comorbidity was associated with advanced age and male gender which 
may explain the association with predominantly cholestatic liver injury17.
An interesting observation in our cohort was that herbal and dietary supplements were 
almost exclusively implicated in patients with no or mild comorbidity as scored by the CCI, 
with no deaths amongst those patients. Based on this finding, DILI related to herbal and 
dietary supplements might then be expected to result in lower mortality. However, this was 
not observed in an analysis of the whole prospective DILIN cohort, wherein 6-month 
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mortality was similar in cases of herbal and dietary supplement related DILI or other DILI11. 
This could be explained by younger age of patients using herbal and dietary supplements 
with mild or no comorbidities.
We observed lower alanine transaminase levels at presentation in patients with significant 
comorbidity. This may be explained by similar findings in patients with acute liver failure 
and underlying non-cirrhotic liver disease18. The higher rate of cholestatic pattern liver 
injury in patients with significant comorbidity who are older and with potential lower 
capacity for liver regeneration19, 20. While the pattern of liver injury was not associated with 
6-month mortality per se, we observed cholestatic injury in 5 of the 10 patients with liver-
related death, and in 5 of 16 with non-liver related death. Whereas, cholestatic liver injury 
was observed in 1 of 6 patients with DILI-related death, in contrast with 9 of 20 patients 
with non-DILI related death. The latter finding supports the postulation of the late Hy 
Zimmerman that most patients with cholestatic DILI die from something other than DILI21.
The strengths of the study include the prospective design of the DILIN study and 
standardized phenotyping of patient factors and both liver and non-liver related outcomes in 
both the study and validation cohorts. This analysis demonstrates that, while the majority of 
patients with suspected DILI have no or mild comorbidity, a sizable subset (93/593 (15.7%)) 
has significant comorbidity. The latter patients have higher short-term mortality with or 
without DILI as the etiology of liver injury. Significant medical comorbidity was an 
independent risk factor for 6-month mortality. The resulting model, incorporating severity of 
comorbidity, MELD and albumin was externally validated and calibrated. A practical 
calculator was developed to facilitate stratification of mortality risk in patients with 
suspected DILI in clinical practice. There are several limitations to note. The model was 
based on single center data and the medical comorbid conditions comprising the CCI were 
not all systematically documented per protocol and therefore may be incomplete in some 
instances. In addition, the subgroup of patients with significant comorbidities in both the 
study and validation cohorts were relatively small. Further examination of comorbidity 
burden and outcomes of DILI in larger and geographically diverse cohorts would be helpful.
In summary, we observed that medical comorbidity burden is significantly associated with 6 
month and overall mortality in individuals with suspected DILI. A model consisting of 
Charlson Comorbidity Index, MELD score, and serum albumin strongly predicts 6 month 
mortality in patients with suspected DILI. It identifies patients in need of closer 
comprehensive monitoring in the wake of acute liver injury.
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What you need to know:
BACKGROUND AND CONTEXT: We identified a strong relationship between 
significant comorbidity burden and outcomes of patients with suspected drug-induced 
liver injury (DILI), and developed and validated a model to calculate risk of death within 
6 months.
NEW FINDINGS: Our model calculates risk of death within 6 months for patients with 
suspected DILI based on comorbidity burden, model for end-stage liver disease score, 
and serum level of albumin.
LIMITATIONS: This was a post-hoc analysis of data from 2 centers enrolling patients 
into a prospective study.
IMPACT: Our model can accurately determine risk of death within 6 months for patients 
with suspected DILI using easily available bedside variables.
Lay Summary: We developed a system to determine risk of death in patients suspected 
of having drug-induced liver injury.
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Survival in patients with significant comorbidity (Charslon Comorbidity Index > 2) (dashed 
line) vs. mild comorbidity (Charlson Comorbidity Index ≤ 2) (solid line) using the Kaplan-
Meier method in patients with suspected drug-induced liver injury (DILI) in the Indiana 
University Cohort (Figure 1-A) and University of North Carolina cohort (Figure 1-B).
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A calculator that incorporates Charlson Comorbidity Index, Model for End-stage Liver 
Disease (MELD) and serum albumin in predicting 6-month mortality in patients with 
suspected acute drug-induced liver injury. Points are assigned for Charlson Comorbidity 
Index, MELD and serum albumin scales using the linear points scale at the top of the figure. 
The risk of 6-month mortality correlating with the total points is on the two linear scales at 
the bottom of the figure.
Two cases are provided as examples to demonstrate the use of the calculator. A patient 
presenting with CCI 0 (0 points), serum albumin 3 g/dL (41 points) and MELD 10 (12 
points), will have a total of 53 points and corresponding 25% probability of 6-month 
mortality. A patient presenting with CCI 5 (50 points), serum albumin 2.9 g/dL (44 points) 
and MELD 23 (50 points) has a total of 143 points with 36% probability of 6-month 
mortality.
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Table 1.
Selected characteristics of patients with suspected drug-induced liver injury (DILI) according to Charlson 











Age (years) 49 ± 19 47 ± 19 57 ± 15 <0.001
Male (%) 48 43 70 <0.001















Latino ethnicity (%) 5.9 5.9 6 >0.999
Latency (days) 161± 506 139±481 267±610 0.7
Serum ALT (IU/L) 745 ± 996 806±1062 439±452 0.001
Serum Alk Phos (IU/L) 297 ± 306 274 ± 226 408±539 0.17
Serum bilirubin (mg/dL) 6.3 ± 5.6 6.5 ± 5.6 5.4 ± 5.6 0.08
INR (at onset)









Serum creatinine (mg/dL) 1.2 ± 0.6 1.2 ± 0.5 1.6 ± 1 <0.001
MELD 15.7 ± 6.7 15.3 ± 6.3 17.9 ± 8.2 0.037
Albumin (g/dL) 3.4 ± 0.7 3.5 ± 0.7 3± 0.7 <0.001









































Number of implicated agents 1.4 ± 0.7 1.4 ± 0.7 1.6 ± 0.8 0.08
Number of concomitant drugs 8.7 ± 8.7 7.6 ± 8 13.8 ± 9.7 <0.001
Number of comorbidities included in CCI 0.84 ± 1.25 0.42 ± 0.61 2.85 ± 1.56 <0.001




Liver disease mild / moderate to severe
Peripheral vascular disease
Renal disease (moderate to severe)
Congestive heart failure

































































































Values shown as mean ± standard deviation unless specified otherwise;
**
P-values compare No/mild comorbidity and significant comorbidity groups.
Abbreviations: ALT: Alanine aminotransferase; Alk P: Alkaline Phosphatase; CCI, Charlson Comorbidity Index; DILI, Drug-induced liver 
injury; INR, International Normalized Ratio; MELD, Model for End-stage Liver Disease; NA, not applicable.
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Table 2.
Factors at presentation associated with 6-month overall mortality in patients with suspected drug-induced liver 
injury (N=306)







Reference category none/mild comorbidity (CCI≤2)













Age (years) 1.03 (1.005, 1.054)
p=0.02
¶
Factors not associated with 6-month mortality on simple logistic regression included gender, race, ethnicity, body mass index and pattern of liver 
injury at onset.
Abbreviations: CCI, Charlson Comorbidity Index; CI, Confidence Interval; DILI, Drug-Induced Liver Injury; MELD, Model for End-stage Liver 
Disease; OR, Odds Ratio.
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Table 3.
Relationship between comorbidity burden and 6-month and overall mortality in patients with DILI, stratified 
according to MELD ≤ 19 vs MELD>19¶
MELD ≤19 (low risk) P value




6-month mortality (%) 2.4 20 <0.001
Overall mortality (%) 4.8 26.7 <0.001
MELD >19 (high risk)




6-month mortality (%) 13.3 39.1 0.015
Overall mortality (%) 13.3 39.1 0.015
Abbreviations: CCI, Charlson Comorbidity Index; MELD, Model for End-stage Liver Disease.
¶
MELD ≤ 19 and >19 were categorized as low-risk and high-risk categorized based on Ref 3.
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